Indication
Treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older.
Loading your page…
Loading your page…
Epidermolysis Bullosa Dystrophica;Epidermolysis Bullosa, Junctional
Marketing Authorisation Holder: Chiesi Farmaceutici S.p.A
EMA Authorisation: 21/06/2022
INN: birch bark extract
AI Drug & Interaction Analysis
Free account required
Ask Osler about Filsuvez: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.